FDA Adverse Event Malfunction Summary report: N

ON-Q SILVERSOAKER

MDR report key: 2043351 · Received February 25, 2011

Report

Report Number
2026095-2011-00052
Event Type
Malfunction
Date Received
February 25, 2011
Date of Event
September 18, 2008
Report Date
September 19, 2008
Manufacturer
I-FLOW CORP.
Product Code
MEB
PMA / PMN Number
K063530
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
DE, US
Reporter Occupation
PHARMACIST

Narratives

Additional Manufacturer Narrative · 1

THE DIRECTIONS FOR USE (DFU) (1304267, REV. G): "CAUTION: DO NOT FILL LESS THAN MINIMUM OR EXCEED MAXIMUM FILL VOLUME." THE MAXIMUM FILL VOLUME FOR THIS PUMP IS 335ML. THE REPORTED FILL VOLUME WAS 340ML. IN ADDITION, THE DFU STATES: "FILLING THE PUMP LESS THAN NOMINAL, INCREASE FLOW RATE. FILLING THE PUMP GREATER THAN NOMINAL, DECREASE FLOW RATE." THE DFU ALSO INDICATES THAT WHEN FILLED TO NOMINAL VOLUME, FLOW RATE ACCURACY IS +/-15% OF THE LABELED FLOW RATE WHEN INFUSION IS STARTED 0-8 H AFTER FILL AND DELIVERING NORMAL SALINE AS THE DILUENT AT 88 DEGREES F (31 DEGREES C) AGAINST A BACK PRESSURE OF 40CM OF WATER. A REVIEW OF THE LOT HISTORY SHOWED NO OTHER COMPLAINTS FOR THIS LOT. A DEVICE HISTORY RECORD WAS CONDUCTED, AND ALL MFG OPERATIONS WERE FOUND TO BE WITHIN SPEC. I-FLOW RECEIVED ONE EMPTY AND USED PUMP FOR EVAL AND INVESTIGATION. THE PUMP WAS REFILLED WITH NORMAL SALINE SOLUTION TO THE REPORTED FILL VOLUME OF 340ML AND A FLOW RATE ACCURACY TEST WAS PERFORMED. THE PUMP WAS FOUND TO MEET SPEC. PRODUCT COMPLAINT IS NOT CONFIRMED FOR FAST FLOW.

Description of Event or Problem · 1

(DRUG/DILUENT: ROPIVACAINE 0.25%). THE PUMP WAS REPORTED TO FLOW FOR 48 HOURS AND FILLED AT 340ML AND FLOW AT 5ML/HR. THIS IS OVER THE MAXIMUM FILL VOLUME FOR THIS PART NUMBER. NO ADVERSE EVENT OCCURRED. PER DFU: NOMINAL FILL VOLUME: 270ML AND NOMINAL FLOW RATE: 5ML/HR.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ON-Q SILVERSOAKER ELASTOMERIC PUMP MEB I-FLOW CORP. PM014-A 852804

Patients

Seq Age Sex Outcome Treatment
1 UNK